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 Background & aims: thyroid disorders are frequently associated 
with diabetes in clinical practice. The purpose of this study is to assess the 
prevalence of euthyroid diffuse goiter (edg) in a group of adults with 
diabetes mellitus (dm) and other changes in glycemic balance. Methods: the 
studied group was of 650 people with dm and other changes in glycemic 
balance, aged between 18 - 79 years. The methods of investigation were 
represented by clinical, imaging, biochemical, hormonal and immunological 
parameters. Results: the prevalence of edg in the study group was 37.84% 
(38.43% f and 32.25% m, p = 0.34, x2 = 0.91). Edg prevalence in type 1 
diabetic group was 1.66% (1.81% f and 0% m, p = 0.76, x2 = 0.09), 43.1% in 
type 2 diabetic group (44.04% f and 36.84% m, p = 0.4, x2 = 0.7), 44.26% in 
igt group (43.93% f and 50% m, p = 0.7, x2 = 0.14), and 33.33% in ifg group 
(35.18% f and 11.11% m, p = 0.14, x2 = 2.17). Significant differences 
regarding edg prevalence were found between the group with type 1 and type 
2 diabetes and other changes in glycemic balance, but not between type 2 
diabetes and other changes in glycemic control. Conclusions: there were not 
significant differences regarding gender in patients with edg and dm or other 
changer in glycemic balance. We noticed no association with type 1 diabetes 
(autoimmune disease), but only with dm type 2 and other changes in 
glycemic balance.  
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Introduction: 
Euthyroid goiter is defined as thyroid enlargement with normal 
thyroid function. There are three forms: diffuse goiter, multinodular goiter 
and a solitary thyroid nodule.  
 The diagnosis of euthyroid goiter is based on palpation of the thyroid 
and evaluation of thyroid function. If the thyroid is enlarged, the examiner 
should determine whether the enlargement is diffuse or multinodular, or 
whether a single nodule is palpable. (Clutter, 2013) 
 All three forms of euthyroid goiter are common, especially in 
women. Imaging studies, such as thyroid scans or ultrasonography, provide 
no useful additional information about goiters that are diffuse or 
multinodular by palpation and should not be performed in these patients. 
Furthermore, 20% to 60% of people have no palpable thyroid nodules that 
are detectable by ultrasound. These nodules rarely have any clinical 
importance, but their incidental discovery may lead to unnecessary 
diagnostic testing and treatment. (Clutter, 2013) 
 Almost all euthyroid diffuse goiters in iodine – sufficient regions 
such as united states are caused by chronic lymphocytic thyroiditis 
(hashimoto’s thyroiditis). Iodine deficiency also causes diffuse colloid goiter 
in much of the world. Because hashimoto’s thyroiditis may also cause 
hypothyroidism, plasma thyroid – stimulating hormone (tsh) should be 
measured even in patients who are clinically euthyroid. The presence of 
antithyroid antibodies confirms the diagnosis of hashimoto’s disease, but this 
test is seldom needed. Thyroid imaging should not be performed. (Clutter, 
2013) 
 Another causes of euthyroid diffuse goiter are: excess iodine (wolff-
chaikoff effect) (Duarte et al, 2009) or lithium ingestion, which decrease 
release of thyroid hormone, goitrogens, stimulation of tsh receptors by tsh 
from pituitary tumours, pituitary thyroid hormone resistance, gonadotropins, 
and/or thyroid-stimulating immunoglobulins , inborn errors of metabolism 
causing defects in biosynthesis of thyroid hormones, exposure to radiation, 
deposition diseases, thyroid hormone resistance, subacute thyroiditis (de 
quervain thyroiditis), silent thyroiditis, riedel thyroiditis, infectious agents : 
acute suppurative – bacterial and chronic - mycobacteria, fungal, and 
parasitic, granulomatous disease, thyroid malignancy and low selenium 
levels. (Rasmussen et al, 2011)  
 The frequency of euthyroid diffuse goiter varies around the world. In 
united states, autopsy studies suggest a frequency of greater than 50% for 
thyroid nodules; with high-resolution ultrasonography, the value approaches 
40% of patients with nonthyroidal illness. In the wickham study from the 
united kingdom, 16% of the population had a goiter. (tunbridge et al, 1977) 
in the framingham study, ultrasonography revealed that 3% of men older 
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than 60 years had thyroid nodules, while 36% of women aged 49-58 years 
had thyroid nodules. (Sawin et al, 1989) in the united states, most goiters are 
due to autoimmune thyroiditis (i.e., Hashimoto disease). (Clutter, 2013)  
The incidence of thyroid cancer has been rising worldwide. The 
reasons are unclear, but this trend may be related to better detection and 
diagnostic methods. (Cossu et al, 2013)  
Worldwide, the most common cause of goiter is iodine deficiency. 
(triggiani et al, 2009) it is estimated that goiters affect as many as 200 
million of the 800 million people who have a diet deficient in iodine. 
In a german study, 635 people underwent ultrasonographic thyroid 
screening, as well as basal tsh measurement, during preventive-health 
checkups. (Guth et al, 2009) thyroid nodules were detected in 432 (68%) of 
the persons screened; in a previous german study, ultrasonographic screening 
of more than 90,000 people detected thyroid nodules in 33% of the normal 
population. The authors of the latter report attributed this difference to the 
fact that patients in their study were screened using 13 mhz ultrasonographic 
scanners, which were more sensitive than the 7.5 mhz scanners used in the 
previous study. According to the investigators, their results indicated that the 
question of routine iodine supplementation requires renewed attention.  
No racial predilection exists. 
The female-to-male ratio is 4:1. 
In the wickham study, 26% of women had a goiter, compared to 7% 
of men. (Tunbridge et al, 1977)  
Thyroid nodules are less frequent in men than in women, but when 
found, they are more likely to be malignant. 
Fine-needle aspiration biopsy is used for cytological diagnosis. 
(Bardin, 1997)  
The frequency of goiters decreases with advancing age. The decrease 
in frequency differs from the incidence of thyroid nodules, which increases 
with advancing age.  
Most goiters are benign, causing only cosmetic disfigurement. 
Morbidity or mortality may result from compression of surrounding 
structures, thyroid cancer, hyperthyroidism, or hypothyroidism. 
 Diffuse goiter is diagnosed by thyroid palpation. Imaging is not 
needed and often detects incidental, clinically unimportant nodules.  
 small diffuse goiters usually are asymptomatic, and therapy is seldom 
required. Large goiters may cause compressive symptoms such as dysphagia, 
dyspneea, or neck fullness.  
 Patients should be followed annually with thyroid palpation and 
measurement of plasma tsh to monitor for development of hypothyroidism. 
Most diffuse goiters do not progressively enlarge, but in a few, 
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thyroidectomy may be needed to relieve compressive symptoms or for 
cosmetic reasons.  
 
I. 
Material and methods 
Investigated population 
650 people with diabetes and other changes in glycemic balance (588 
f and 62 m) aged between 18 and 79 years represented the study group.  
Depending on glycemic balance the group was divided into:  
- the group with dm type 1 - 60 
- the group with dm type 2 - 290 
- the group with igt - 183 
- the group with ifg – 117 
Fig. 1. Cases distribution according to the type of changes in glycemic balance 
 
Methods of investigation 
The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated haemoglobin, 
investigation of the thyroid gland: tsh, ft4, ft3, thyroid antibodies. 
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the ogtt at 2 h between 140 - 
200 mg% and impaired fasting glucose - values between 110 - 125 mg% and 
ogtt at 2 h under 140 mg%.  
Determination of hba1c was achieved through the diastat for 
measuring hba1c reported to the total hba.  
To determine the tsh level in plasma, the free fraction of 
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performed a quantitative method architect; witch is an immunological 
method, chemilumnescent micro particle immunoassay (cmia). Normal 
values were following: tsh = 0.465-4.68 miu/ml, ft3 = 3.69 -10.4 pmol/l, ft4 
= 10-28.2 pmol/l. 
The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antitpo and antitg antibodies).  
To determine serum levels of antitpo antibodies it was used the kit 
axsym antitpo, an immunological method (micro particle enzyme 
immunoassay) (meia). Normal values:  antitpo antibodies <35 iu/ml.  
To determine serum levels of antitg antibodies it was used the kit 
axsym antitg, a meia method as well (micro particle enzyme immunoassay). 
Normal values: antitg antibodies <55 iu/ml.  
Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
An increased density, uniform, characterizes normal thyroid 
parenchyma easily distinguished from the neck muscles that are hypo dens.  
Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
Chronic autoimmune thyroid disorder appears with a hypoecogenity 
of the parenchyma and normal or increased thyroid volume.  
 
Statistical analysis 
For statistical analysis we used microsoft excel and pop tools from 
microsoft office 2003 and epi 2000 program. To measure the quantitative 
variables were determined average and standard deviation, and to assess the 
gender differences and other differences we used the unpaired t test and 
anova test, considering statistically significant a p < 0.05. 
 
Results and discussion 
Adults group included 650 people, young adults, adults and the 
elderly, aged between 17 and 79 years. It consisted of subjects with diabetes 
which in time present thyroid diseases and subjects with thyroid disease who 
have developed glucose metabolism disorders or diabetes.  
Adults group was subdivided according to the type of change in 
glycemic balance in four subgroups (fig. 1):  
- group with dm type 1 with 60 cases (9.23%)  
- group with dm type 2 with 290 cases (44.61%)  
- igt group with 183 cases (28.15%)  
European Scientific Journal January 2015 edition vol.11, No.3 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
33 
- ifg group with 117 cases (18%) 
Euthyroid diffuse goiter is characterized by overall increase in 
volume of the thyroid gland that is not attributable to inflammatory processes 
or neoplastic, being not associated with functional disturbances. In the 
general population, its prevalence is about 10% (Wartofski, 2001) 
the prevalence of euthyroid diffuse goiter in the study group was 
37.84% (38.43% f and 32.25% m, p = 0.34, x2 = 0.91). Euthyroid diffuse 
goiter prevalence in type 1 diabetic group was 1.66% (1.81% f and 0% m, p 
= 0.76, x2 = 0.09), 43.1% in type 2 diabetic group (44.04%f and 36.84% m, p 
= 0.4, x2 = 0.7), 44.26% in igt group (43.93% f and 50% m, p = 0.7, x2 = 
0.14), and 33.33% in ifg group (35.18% f and 11.11% m, p = 0.14, x2 = 2.17) 
(fig. 1 and fig. 2).  
Fig. 2. The prevalence of euthyroid diffuse goiter in the study group 
In the case of euthyroid diffuse goiter, f/m ratio was 1/0 for type 1 dm 
group, 7.9/1 in the case of the group with dm type 2, 15.2/1 for igt group and 
38/1 in the ifg group. In literature f/m ratio is 1.2 to 4.3/1 (Lee et al, 2006). 
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Significant differences regarding euthyroid diffuse goiter prevalence 
were found between the group with diabetes type 1 and type 2 diabetes and 
other changes in glycemic balance (1.66% vs. 43.1%, p<0.001, x2 = 37.05 for 
diabetes type 1 and type 2 diabetes, 1.66% vs. 44.26%, p<0.001, x2 = 39.83 
for type 1 diabetes and igt, 1.66% vs. 33.33%, p<0.001, x2 = 22.74 for type 1 
diabetes and ifg), but not between type 2 diabetes and other changes in 
glycemic control (43.1% vs. 44.26%, p = 0.8, x2 = 0.06 for type 2 diabetes 
and igt, 43.1% vs. 33.33%, p = 0.06, x2 = 3.31 for type 2 diabetes and ifg, 
44.26% vs. 33.33%, p = 0.059, x2 = 3.55 for igt and ifg) (table i).  
Table i. Differences regarding euthyroid diffuse goiter prevalence 
  Dm type 1 Dm type 2 Igt Ifg 
Dm type 1 1.66% - P<0.001 P<0.001 P<0.001 
Dm type 2 43.1% P<0.001 - 0.8 0.06 
Igt 44.26% P<0.001 0.8 - 0.059 
Ifg 33.33% P<0.001 0.06 0.059 - 
 
The average onset age and the medium duration of euthyroid diffuse 
goiter in adults with diabestes mellitus and other changes in glycemic 
balance are described in tables ii and iii. The average onset age for dm type 1 
is 38 years and for dm type 2, igt and ifg is between 45 – 50 years. In the 
case of dm type 1 the thyroid disease appears after 18 years (this association 
is random) and for dm type 2, igt and ifg after 0.5 – 7 years (after 
administration of thyroid hormones).  
Table ii. Average onset age of euthyroid diffuse goiter in adults with diabetes mellitus and 
other changes in glycemic balance  
Type of changes 
in glycemic 
balance 
Case number Average Standard deviation Median 
Dm type 1 1 38 - 38 
Dm type 2 125 50.67 13.06 50 
Igt 81 43.54 15 45 
Ifg 39 46.64 14.51 47 
 
Table iii. Medium duration of euthyroid diffuse goiter in adults with diabetes mellitus and 








deviation Median Minimum Maximum 
Dm type 1 1 18 - 18 18 18 
Dm type 2 125 0.5 7.71 1 0 38 
Igt 81 6.01 10.01 1 0 43 
Ifg 39 7 9.99 2 0 42 
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In the case of euthyroid diffuse goiter, was absent symptoms, and 
diagnosis was based on clinical examination and ultrasound. 
Table iv. Distribution after goiter stages of adult’s patients with euthyroid diffuse goiter and 







0 1a 1b 2 3 
n % n % n % n % n % 
Dm type 
1 - - - - - - 1 100 - - 
Dm type 
2 51 40.8 43 34.4 12 9.6 12 9.6 7 5.6 
Igt 28 34.57 34 41.97 10 12.34 9 11.11 - - 
Ifg 14 35.9 11 28.2 6 15.38 7 17.95 1 2.56 
 
The most common cause of goiter developing is iodine deficiency. In 
patients who do not come from regions with iodine deficiency, the cause is 
obscure (Lee et al, 2006). 
Sporadic goiter incidence in north america is estimated at 5%. 
Usually not appear before puberty and not shows a peak incidence. Generally 
goiter development increases with age. The prevalence of palpable nodules is 
approximately 5-6% in people aged 60 years, but at ultrasound examination, 
the incidence of impalpable nodules reach 50% in persons aged 60 years (lee 
et al, 2006). 
Who, unicef and iccidd considers that in the absence of iodine 
deficiency goiter prevalence is below 5%, slightly iodine deficiency is 
associated with a prevalence of 5-20%, moderate iodine deficiency with a 
prevalence of 20-30% and severe iodine deficiency with a prevalence of 30% 
(Lee et al, 2006). Goiter is predominant in women, the ratio f/m being 1.2 to 
4.3/1 (Lee et al, 2006). Some studies have shown that treatment at sporadic 
goiter with t4 decreased thyroid volume to 58% of patients compared to 4% 
of patients treated with placebo. When instituting therapy with t4 is should 
be considered sub clinical hyperthyroidism risks that are associated with 
various metabolic and visceral complications (Lee et al, 2006). Diffuse 
goiter, with hard consistency, fast growing, with compressive symptoms and 
regional lymphadenopathy are sometimes suspicious of malignancy. 
Studies show variable correlation between physical exam findings 
and findings on imaging studies. In a retrospective chart review, ultrasound 
findings differed from clinical exam findings in 63% of cases. (Marqusee et 
al, 2000) thyroid ultrasound is less expensive and less invasive than other 
imaging modalities, provides excellent visualization of thyroid structure and 
the nature of cysts and nodules, and allows for estimation of thyroid size. 
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Computed tomography and magnetic resonance imaging perform 
better for visualization of extension of thyroid tissue substernally and are 
also preferred for evaluation of the neck in cases of severe local 
complications of goiter, such as compressive symptoms. (hurley et al, 1996) 
The malignant potential in multinodular goiter (2%–4%) is similar to 
that of solitary nodules (4%–6%). (hurley et al, 1996) therefore, any 
dominant nodule in a multinodular goiter should be evaluated the same way 
one would evaluate a solitary nodule. 
Thyroid ultrasound allows accurate assessment of thyroid volume and 
appreciation of thyroid parenchyma aspect. 
After the study of iodine intake in banat plain, especially in the area 
of timisoara, the normal thyroid volumes were within the following values: 
women - 10.27 ± 2.09 ml and in men - 12.18 ± 2.52 ml. 
In our case, the goiter has been diagnosed at thyroid volume that 
exceeded 3 sd (females > 16.54 ml and in men > 19.74 ml). 






Tv type Hypoecognicity type 
Normal Increase Mild Medium Intense 
n % n % n % n % n % 
Dm type 
1 - - 1 100 1 100 - - - - 
Dm type 
2 44 35.2 81 64.8 95 76 - 30 24 - 
Igt 17 20.99 64 79.01 66 81.48 15 18.52 - - 
Ifg 9 23.07 30 76.92 28 71.79 11 28.21 - - 
 
Euthyroid diffuse goiter was encountered in 1 patient with type 1 
diabetes, at 125 patients with type 2 diabetes, at 81 patients with igt and at 39 
patients with ifg. In all these, hormonal functional parameters were within 
normal limits. 
Table vi. Tsh and ft4 values in patients with euthyroid diffuse goiter 
Parameters Dm type 1 (n = 1) 
Dm type 2 
(n = 125) 
Igt 
(n = 81) 
Ifg 
(n = 39) 
Tsh (miu/ml) 1.14 1.82 ± 1.14 2.17 ± 1.21 2.83 ± 1.15 
Ft4 (pmol/l) 15 14.96 ± 4.49 14.5 ± 3.71 16.1 ± 3.76 
 
Depending on the value of tsh was performed functional 
classification of cases. All cases with diffuse goiter functionally were 
euthyroid. 
Patients with a reassuring initial workup can be followed clinically 
and should be assessed with serial clinical evaluations. No evidence could be 
found regarding optimal intervals for examination and testing; yearly exams 
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and tsh testing are considered adequate by some experts. (Berghout et al, 
1990).  
Because a few non-benign conditions such as thyroiditis and 
neoplasm can sometimes present in a euthyroid state, the clinician should be 
alert for any physical exam or laboratory changes. If any changes occur, then 
further workup is indicated. 
Suppressive therapy with thyroxin is an option for decreasing thyroid 
size in euthyroid goiter, but this therapy remains controversial. One placebo 
controlled trial of thyroid suppression in non-toxic multinodular goiter 
showed regression of thyroid size with suppressive therapy (58% reduction 
in size in treatment group vs. 5% reduction in control group). However, not 
all goiters responded to this therapy, and the thyroid size returned to pre-
treatment size within 9 months of discontinuation of suppressive therapy. 
(Berghout et al, 1990).  
Many experts argue against the use of suppressive therapy in long-
standing goiters, citing less response from these patients, along with concern 
about side effects and possible over suppression, but the evidence in this area 
is limited. Patients who are treated with thyroxin should be followed for 
possible side effects of the medication, including arrhythmia and osteopenia, 
particularly in elderly patients and those who take the medication for long 
periods. 
Guidelines from the american association of clinical endocrinology’s 
task force on thyroid nodules, released in 2006, recommends ultrasound be 
used routinely in the case of multinodular goiter to assist with diagnosis, 
detect suspicious nodules that may require biopsy, and to serve as an 
objective baseline measure. This group recommends against use of 
suppression therapy in long-standing goiters. (aace/ame, 2006) 






None Suppression Inhibition Surgery 
n % n % n % n % 
Dm type 1 - - 1 100  - - - - 
Dm type 2 28 22.4 87 69.6 - - 10 8 
Igt 10 12.34 61 75.3 - - 10 12.34 
Ifg 4 10.25 30 76.92 - - 5 12.82 
 
In the case of euthyroid diffuse goiter and dm type 1 all cases 
receiving suppression treatment with thyroid hormone. 
In the case of euthyroid diffuse goiter and dm type 2, 22.4% of the 
cases did not require any treatment. A percentage of 69.6% of patients 
receiving suppression treatment with thyroid hormone and 8% cases required 
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surgical intervention due to the presence of higher goiter, with compression 
phenomena.  
In the case of euthyroid diffuse goiter and igt, 12.34% of the cases 
did not require any treatment, a percentage of 75.3% of patients have 
received suppression treatment with thyroid hormone and 12.34% of patients 
had required surgical intervention due to the presence of a higher goiter, with 
compression phenomena. 
In the case of euthyroid diffuse goiter and ifg, 10.25% of the cases 
did not require any treatment. A percentage of 76.92% of patients receiving 
suppression treatment with thyroid hormone and 12.82% cases required 
surgical intervention due to the presence of higher goiter, with compression 
phenomena. 
 If thyroid disorder was the first appearance, the administrations of 
excess thyroid hormone or thyroid hormone imbalance led to an unbalance 
of a pre-existing type 2 diabetes or to the unmasking of latent one, and the 
appearance of igt and ifg. Type 2 diabetes that appeared was mild, requiring 
only dietary treatment. 
 
Conclusion 
 There were not significant differences regarding gender in patients 
with euthyroid diffuse goiter and diabetes mellitus or other changer in 
glycemic balance. 
  We noticed no association with type 1 diabetes (autoimmune 
disease), but only with diabetes mellitus type 2 and other changes in 
glycemic balance.  
 In the case of dm type 1 the association was random, and on the case 
of dm type 2, igt and ifg, these appear in the first 10 years after thyroid 
disease, due to the administration of thyroid hormones. 
 In all patients with euthyroid diffuse goiter, hormonal functional 
parameters were within normal limits. Some of them receive suppression 
treatment with thyroid hormones and some of the patients had required 
surgical intervention due to the presence of a higher goiter, with compression 
phenomena. 
 If thyroid disorder was the first appearance, the administrations of 
excess thyroid hormone or thyroid hormone imbalance led to an unbalance 
of a pre-existing type 2 diabetes or to the unmasking of latent one, and the 
appearance of igt and ifg. Type 2 diabetes that appeared was mild, requiring 
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